Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy : present status, future prospects and limitations
Elevated renal uptake and prolonged retention of radiolabeled antibody fragments and peptides is a problem in the therapeutic application of such agents. Over recent years, one of the focuses of research has therefore been to develop suitable methods to reduce this renal uptake, and to evaluate whet...
Gespeichert in:
Veröffentlicht in: | European journal of nuclear medicine 1998-02, Vol.25 (2), p.201-212 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 212 |
---|---|
container_issue | 2 |
container_start_page | 201 |
container_title | European journal of nuclear medicine |
container_volume | 25 |
creator | BEHR, T. M GOLDENBERG, D. M BECKER, W |
description | Elevated renal uptake and prolonged retention of radiolabeled antibody fragments and peptides is a problem in the therapeutic application of such agents. Over recent years, one of the focuses of research has therefore been to develop suitable methods to reduce this renal uptake, and to evaluate whether the resulting methodology will benefit therapy with antibody fragments and peptides. In these studies it has been shown that the kidney uptake of antibody fragments in animals can be reduced in a dose-dependent manner by almost one order of magnitude by the systemic administration of cationic amino acids and their derivatives, whereas the uptake in all other organs, as well as the tumor, remains unaffected. A similar reduction in renal retention is achieved for all intracellularly retained radionuclides (e.g., radiometals) or radioiodinated immunoconjugates, as well as for smaller peptides. Lysine is usually the preferred agent, and its d- and l-isomers are equally effective whether given intraperitoneally or orally. Amino sugars are effective, but their N-acetyl derivatives, lacking the positive charge, are not. Basic polypeptides are also effective, and their potency increases with increasing molecular weight (i.e., the amount of positive charges per molecule). Urine analysis of treated individuals shows the excretion of unmetabolized, intact fragments or peptides, in contrast to mostly low-molecular-weight metabolites in untreated controls. In therapy studies using radiometal-conjugated Fab fragments, the kidney is the first dose-limiting organ. Administration of cationic amino acids results in a substantial increase in the maximum tolerated dose of such Fab fragments. No biochemical or histological evidence of renal damage has been observed under these conditions. As was the case in animal studies, in pilot clinical trials the renal uptake in patients injected with Fab' fragments and given amino acids could be decreased significantly, whereas the uptake by all other organs remained unaffected. These recent studies indicate that a variety of basic compounds are capable of inhibiting the tubular reabsorption of peptides and proteins, thus significantly lowering the renal uptake of antibody fragments or peptides in both animals and patients. On a molecular basis, the effect seems to rely essentially on the presence of a positively charged amino group. Thus, radiation nephrotoxicity of antibody fragments and peptides can be overcome successfully; this may pr |
doi_str_mv | 10.1007/s002590050216 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1038761435</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2756329681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-827d1e75e68afe5666aa87ee8dc1e7e98ff569b913543bd1ad7e57afee55ad93</originalsourceid><addsrcrecordid>eNpVkU9r3DAQxUVJSLZpjz0WBM2xTqSVJVm9hZD-gUCh5G7G1mir1Gs7GvmwXySfNyprAjkNvPebx_CGsU9SXEkh7DUJsdVOCC220rxjG2mkq6xo3AnbCFWLyjhnz9l7okchRF0rfcbOXG3V1soNe_6DfunjuOP5L_KEIwx8mTP8Qz4FnsDHaYAOB_Qcxhy7yR94SLDb45ipSJ7POOfokXiYEvcRduNE8WiVyATzgX_jc0IqG5wy5IW-8rDkJWGRJ5qxX5OGuI_Fj9NIH9hpgIHw4zov2MP3u4fbn9X97x-_bm_uq76WMlfN1nqJVqNpIKA2xgA0FrHxfZHRNSFo4zonla5V5yV4i9oWFLUG79QF-3KMLYc8LUi5fZyWVDqgVgrVWCNLXYWqjlRfzqWEoZ1T3EM6FKj9_4P2zQ8K_3lNXbo9-ld6Lb34l6sP1MNQ6hz7SK9YiWi0MuoFWgSRuA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1038761435</pqid></control><display><type>article</type><title>Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy : present status, future prospects and limitations</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>BEHR, T. M ; GOLDENBERG, D. M ; BECKER, W</creator><creatorcontrib>BEHR, T. M ; GOLDENBERG, D. M ; BECKER, W</creatorcontrib><description>Elevated renal uptake and prolonged retention of radiolabeled antibody fragments and peptides is a problem in the therapeutic application of such agents. Over recent years, one of the focuses of research has therefore been to develop suitable methods to reduce this renal uptake, and to evaluate whether the resulting methodology will benefit therapy with antibody fragments and peptides. In these studies it has been shown that the kidney uptake of antibody fragments in animals can be reduced in a dose-dependent manner by almost one order of magnitude by the systemic administration of cationic amino acids and their derivatives, whereas the uptake in all other organs, as well as the tumor, remains unaffected. A similar reduction in renal retention is achieved for all intracellularly retained radionuclides (e.g., radiometals) or radioiodinated immunoconjugates, as well as for smaller peptides. Lysine is usually the preferred agent, and its d- and l-isomers are equally effective whether given intraperitoneally or orally. Amino sugars are effective, but their N-acetyl derivatives, lacking the positive charge, are not. Basic polypeptides are also effective, and their potency increases with increasing molecular weight (i.e., the amount of positive charges per molecule). Urine analysis of treated individuals shows the excretion of unmetabolized, intact fragments or peptides, in contrast to mostly low-molecular-weight metabolites in untreated controls. In therapy studies using radiometal-conjugated Fab fragments, the kidney is the first dose-limiting organ. Administration of cationic amino acids results in a substantial increase in the maximum tolerated dose of such Fab fragments. No biochemical or histological evidence of renal damage has been observed under these conditions. As was the case in animal studies, in pilot clinical trials the renal uptake in patients injected with Fab' fragments and given amino acids could be decreased significantly, whereas the uptake by all other organs remained unaffected. These recent studies indicate that a variety of basic compounds are capable of inhibiting the tubular reabsorption of peptides and proteins, thus significantly lowering the renal uptake of antibody fragments or peptides in both animals and patients. On a molecular basis, the effect seems to rely essentially on the presence of a positively charged amino group. Thus, radiation nephrotoxicity of antibody fragments and peptides can be overcome successfully; this may provide new prospects for cancer therapy with radiolabeled antibody fragments and peptides.</description><identifier>ISSN: 0340-6997</identifier><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s002590050216</identifier><identifier>PMID: 9473271</identifier><identifier>CODEN: EJNMD9</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Amino Acids - adverse effects ; Amino Acids - therapeutic use ; Amino Acids - urine ; Animals ; Antibodies - adverse effects ; Antibodies - therapeutic use ; Antibodies - urine ; Biological and medical sciences ; Biotechnology ; Clinical Trials as Topic ; Contrast media. Radiopharmaceuticals ; Forecasting ; Humans ; Immunoglobulin Fab Fragments - adverse effects ; Immunoglobulin Fab Fragments - therapeutic use ; Immunoglobulin Fab Fragments - urine ; Kidney - metabolism ; Kidney - radiation effects ; Medical sciences ; Molecular weight ; Peptides ; Peptides - adverse effects ; Peptides - therapeutic use ; Peptides - urine ; Pharmacology. Drug treatments ; Radiation Dosage ; Radioimmunodetection ; Radiopharmaceuticals - adverse effects ; Radiopharmaceuticals - therapeutic use ; Radiopharmaceuticals - urine</subject><ispartof>European journal of nuclear medicine, 1998-02, Vol.25 (2), p.201-212</ispartof><rights>1998 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 1998</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-827d1e75e68afe5666aa87ee8dc1e7e98ff569b913543bd1ad7e57afee55ad93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2168536$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9473271$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BEHR, T. M</creatorcontrib><creatorcontrib>GOLDENBERG, D. M</creatorcontrib><creatorcontrib>BECKER, W</creatorcontrib><title>Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy : present status, future prospects and limitations</title><title>European journal of nuclear medicine</title><addtitle>Eur J Nucl Med</addtitle><description>Elevated renal uptake and prolonged retention of radiolabeled antibody fragments and peptides is a problem in the therapeutic application of such agents. Over recent years, one of the focuses of research has therefore been to develop suitable methods to reduce this renal uptake, and to evaluate whether the resulting methodology will benefit therapy with antibody fragments and peptides. In these studies it has been shown that the kidney uptake of antibody fragments in animals can be reduced in a dose-dependent manner by almost one order of magnitude by the systemic administration of cationic amino acids and their derivatives, whereas the uptake in all other organs, as well as the tumor, remains unaffected. A similar reduction in renal retention is achieved for all intracellularly retained radionuclides (e.g., radiometals) or radioiodinated immunoconjugates, as well as for smaller peptides. Lysine is usually the preferred agent, and its d- and l-isomers are equally effective whether given intraperitoneally or orally. Amino sugars are effective, but their N-acetyl derivatives, lacking the positive charge, are not. Basic polypeptides are also effective, and their potency increases with increasing molecular weight (i.e., the amount of positive charges per molecule). Urine analysis of treated individuals shows the excretion of unmetabolized, intact fragments or peptides, in contrast to mostly low-molecular-weight metabolites in untreated controls. In therapy studies using radiometal-conjugated Fab fragments, the kidney is the first dose-limiting organ. Administration of cationic amino acids results in a substantial increase in the maximum tolerated dose of such Fab fragments. No biochemical or histological evidence of renal damage has been observed under these conditions. As was the case in animal studies, in pilot clinical trials the renal uptake in patients injected with Fab' fragments and given amino acids could be decreased significantly, whereas the uptake by all other organs remained unaffected. These recent studies indicate that a variety of basic compounds are capable of inhibiting the tubular reabsorption of peptides and proteins, thus significantly lowering the renal uptake of antibody fragments or peptides in both animals and patients. On a molecular basis, the effect seems to rely essentially on the presence of a positively charged amino group. Thus, radiation nephrotoxicity of antibody fragments and peptides can be overcome successfully; this may provide new prospects for cancer therapy with radiolabeled antibody fragments and peptides.</description><subject>Amino Acids - adverse effects</subject><subject>Amino Acids - therapeutic use</subject><subject>Amino Acids - urine</subject><subject>Animals</subject><subject>Antibodies - adverse effects</subject><subject>Antibodies - therapeutic use</subject><subject>Antibodies - urine</subject><subject>Biological and medical sciences</subject><subject>Biotechnology</subject><subject>Clinical Trials as Topic</subject><subject>Contrast media. Radiopharmaceuticals</subject><subject>Forecasting</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments - adverse effects</subject><subject>Immunoglobulin Fab Fragments - therapeutic use</subject><subject>Immunoglobulin Fab Fragments - urine</subject><subject>Kidney - metabolism</subject><subject>Kidney - radiation effects</subject><subject>Medical sciences</subject><subject>Molecular weight</subject><subject>Peptides</subject><subject>Peptides - adverse effects</subject><subject>Peptides - therapeutic use</subject><subject>Peptides - urine</subject><subject>Pharmacology. Drug treatments</subject><subject>Radiation Dosage</subject><subject>Radioimmunodetection</subject><subject>Radiopharmaceuticals - adverse effects</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>Radiopharmaceuticals - urine</subject><issn>0340-6997</issn><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpVkU9r3DAQxUVJSLZpjz0WBM2xTqSVJVm9hZD-gUCh5G7G1mir1Gs7GvmwXySfNyprAjkNvPebx_CGsU9SXEkh7DUJsdVOCC220rxjG2mkq6xo3AnbCFWLyjhnz9l7okchRF0rfcbOXG3V1soNe_6DfunjuOP5L_KEIwx8mTP8Qz4FnsDHaYAOB_Qcxhy7yR94SLDb45ipSJ7POOfokXiYEvcRduNE8WiVyATzgX_jc0IqG5wy5IW-8rDkJWGRJ5qxX5OGuI_Fj9NIH9hpgIHw4zov2MP3u4fbn9X97x-_bm_uq76WMlfN1nqJVqNpIKA2xgA0FrHxfZHRNSFo4zonla5V5yV4i9oWFLUG79QF-3KMLYc8LUi5fZyWVDqgVgrVWCNLXYWqjlRfzqWEoZ1T3EM6FKj9_4P2zQ8K_3lNXbo9-ld6Lb34l6sP1MNQ6hz7SK9YiWi0MuoFWgSRuA</recordid><startdate>19980201</startdate><enddate>19980201</enddate><creator>BEHR, T. M</creator><creator>GOLDENBERG, D. M</creator><creator>BECKER, W</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>19980201</creationdate><title>Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy : present status, future prospects and limitations</title><author>BEHR, T. M ; GOLDENBERG, D. M ; BECKER, W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-827d1e75e68afe5666aa87ee8dc1e7e98ff569b913543bd1ad7e57afee55ad93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Amino Acids - adverse effects</topic><topic>Amino Acids - therapeutic use</topic><topic>Amino Acids - urine</topic><topic>Animals</topic><topic>Antibodies - adverse effects</topic><topic>Antibodies - therapeutic use</topic><topic>Antibodies - urine</topic><topic>Biological and medical sciences</topic><topic>Biotechnology</topic><topic>Clinical Trials as Topic</topic><topic>Contrast media. Radiopharmaceuticals</topic><topic>Forecasting</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments - adverse effects</topic><topic>Immunoglobulin Fab Fragments - therapeutic use</topic><topic>Immunoglobulin Fab Fragments - urine</topic><topic>Kidney - metabolism</topic><topic>Kidney - radiation effects</topic><topic>Medical sciences</topic><topic>Molecular weight</topic><topic>Peptides</topic><topic>Peptides - adverse effects</topic><topic>Peptides - therapeutic use</topic><topic>Peptides - urine</topic><topic>Pharmacology. Drug treatments</topic><topic>Radiation Dosage</topic><topic>Radioimmunodetection</topic><topic>Radiopharmaceuticals - adverse effects</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>Radiopharmaceuticals - urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BEHR, T. M</creatorcontrib><creatorcontrib>GOLDENBERG, D. M</creatorcontrib><creatorcontrib>BECKER, W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BEHR, T. M</au><au>GOLDENBERG, D. M</au><au>BECKER, W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy : present status, future prospects and limitations</atitle><jtitle>European journal of nuclear medicine</jtitle><addtitle>Eur J Nucl Med</addtitle><date>1998-02-01</date><risdate>1998</risdate><volume>25</volume><issue>2</issue><spage>201</spage><epage>212</epage><pages>201-212</pages><issn>0340-6997</issn><issn>1619-7070</issn><eissn>1619-7089</eissn><coden>EJNMD9</coden><abstract>Elevated renal uptake and prolonged retention of radiolabeled antibody fragments and peptides is a problem in the therapeutic application of such agents. Over recent years, one of the focuses of research has therefore been to develop suitable methods to reduce this renal uptake, and to evaluate whether the resulting methodology will benefit therapy with antibody fragments and peptides. In these studies it has been shown that the kidney uptake of antibody fragments in animals can be reduced in a dose-dependent manner by almost one order of magnitude by the systemic administration of cationic amino acids and their derivatives, whereas the uptake in all other organs, as well as the tumor, remains unaffected. A similar reduction in renal retention is achieved for all intracellularly retained radionuclides (e.g., radiometals) or radioiodinated immunoconjugates, as well as for smaller peptides. Lysine is usually the preferred agent, and its d- and l-isomers are equally effective whether given intraperitoneally or orally. Amino sugars are effective, but their N-acetyl derivatives, lacking the positive charge, are not. Basic polypeptides are also effective, and their potency increases with increasing molecular weight (i.e., the amount of positive charges per molecule). Urine analysis of treated individuals shows the excretion of unmetabolized, intact fragments or peptides, in contrast to mostly low-molecular-weight metabolites in untreated controls. In therapy studies using radiometal-conjugated Fab fragments, the kidney is the first dose-limiting organ. Administration of cationic amino acids results in a substantial increase in the maximum tolerated dose of such Fab fragments. No biochemical or histological evidence of renal damage has been observed under these conditions. As was the case in animal studies, in pilot clinical trials the renal uptake in patients injected with Fab' fragments and given amino acids could be decreased significantly, whereas the uptake by all other organs remained unaffected. These recent studies indicate that a variety of basic compounds are capable of inhibiting the tubular reabsorption of peptides and proteins, thus significantly lowering the renal uptake of antibody fragments or peptides in both animals and patients. On a molecular basis, the effect seems to rely essentially on the presence of a positively charged amino group. Thus, radiation nephrotoxicity of antibody fragments and peptides can be overcome successfully; this may provide new prospects for cancer therapy with radiolabeled antibody fragments and peptides.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>9473271</pmid><doi>10.1007/s002590050216</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0340-6997 |
ispartof | European journal of nuclear medicine, 1998-02, Vol.25 (2), p.201-212 |
issn | 0340-6997 1619-7070 1619-7089 |
language | eng |
recordid | cdi_proquest_journals_1038761435 |
source | MEDLINE; SpringerNature Journals |
subjects | Amino Acids - adverse effects Amino Acids - therapeutic use Amino Acids - urine Animals Antibodies - adverse effects Antibodies - therapeutic use Antibodies - urine Biological and medical sciences Biotechnology Clinical Trials as Topic Contrast media. Radiopharmaceuticals Forecasting Humans Immunoglobulin Fab Fragments - adverse effects Immunoglobulin Fab Fragments - therapeutic use Immunoglobulin Fab Fragments - urine Kidney - metabolism Kidney - radiation effects Medical sciences Molecular weight Peptides Peptides - adverse effects Peptides - therapeutic use Peptides - urine Pharmacology. Drug treatments Radiation Dosage Radioimmunodetection Radiopharmaceuticals - adverse effects Radiopharmaceuticals - therapeutic use Radiopharmaceuticals - urine |
title | Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy : present status, future prospects and limitations |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T08%3A53%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reducing%20the%20renal%20uptake%20of%20radiolabeled%20antibody%20fragments%20and%20peptides%20for%20diagnosis%20and%20therapy%20:%20present%20status,%20future%20prospects%20and%20limitations&rft.jtitle=European%20journal%20of%20nuclear%20medicine&rft.au=BEHR,%20T.%20M&rft.date=1998-02-01&rft.volume=25&rft.issue=2&rft.spage=201&rft.epage=212&rft.pages=201-212&rft.issn=0340-6997&rft.eissn=1619-7089&rft.coden=EJNMD9&rft_id=info:doi/10.1007/s002590050216&rft_dat=%3Cproquest_cross%3E2756329681%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1038761435&rft_id=info:pmid/9473271&rfr_iscdi=true |